Adalimumab for cutaneous metastatic Crohnʼs disease

Cury, Dídia Bismara; Moss, Alan C.; Elias, Geraldo; Nakao, Alexandre

doi:10.1002/ibd.21082

Cited by 18 publications

(17 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients who have had a prior infusion reaction to infliximab, certolizumab combined with methotrexate has recently been shown to resolve the cutaneous lesions [55]. Another biologic, adalimumab, has also shown efficacy in inducing and maintaining remission [56, 57]. In fact, adjunct usage of topical tacrolimus 0.1% twice daily with adalimumab has demonstrated improvement [58].…”

Section: Treatmentmentioning

confidence: 99%

Metastatic Crohn’s Disease: An Approach to an Uncommon but Important Cutaneous Disorder

Aberumand

Howard

2017

BioMed Research International

View full text Add to dashboard Cite

Objective. To provide physicians with a clinical approach to metastatic Crohn's disease (MCD). Main Message. Metastatic Crohn's disease, defined as skin lesions present in areas noncontiguous with the gastrointestinal tract, is the rarest cutaneous manifestation of Crohn's disease. MCD lesions vary in morphology and can arise anywhere on the skin. MCD presents equally in both sexes and across age groups. Cutaneous findings may precede, develop concurrently with, or follow gastrointestinal involvement. A detailed history and thorough physical examination including a full-skin exam may help to exclude other dermatoses, as MCD can mimic other common disorders. A biopsy is required for a definitive diagnosis. Treatment options for MCD remain underwhelming due to the lack of randomized control studies and varying responses of reported therapeutic methods. Topical, intralesional, and systemic corticosteroids, antibiotics, traditional immunosuppressants, and surgery have shown mixed results. Recently, biologics have shown promise, even with refractory cases of MCD. Conclusion. MCD is an important cutaneous manifestation of this inflammatory disorder. Although a rare entity, early recognition can provide opportunity for successful therapeutic intervention.

show abstract

Section: Treatmentmentioning

confidence: 99%

Metastatic Crohn’s Disease: An Approach to an Uncommon but Important Cutaneous Disorder

Aberumand

Howard

2017

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Cutaneous CD affects male and female individuals of all ages . It has been reported that 22%‐44% of patients with CD have cutaneous symptoms at some point in their disease course, and 7%‐24% of children have extraintestinal manifestations of CD . It is likely that the true incidence of cutaneous CD, and specifically MCD, is underestimated because of lack of reporting and misdiagnosis.…”

Section: Epidemiologymentioning

confidence: 99%

“…The most common presentation of MCD is genital swelling . Other areas of involvement include the extremities, intertriginous zones, legs, and trunk, with the breast, nipple, ear, and umbilicus reported less often . Some lesions have been reported to be completely asymptomatic, whereas others are pruritic, tender, and painful.…”

Section: Clinical Presentationmentioning

confidence: 99%

“…12,13 Other areas of involvement include the extremities, intertriginous zones, legs, and trunk, with the breast, nipple, ear, and umbilicus reported less often. 2,8,9,13 Some lesions have been reported to be completely asymptomatic, whereas others are pruritic, tender, and painful. The site of MCD does not appear to correlate with symptomology.…”

Section: Clinical Presentationmentioning

confidence: 99%

“…2,12 Other treatments include sulfasalazine ointment, tetracycline hydrochloride ointment, intralesional Kenalog, mesalamine, and oral sulfasalazine. 2,29 For refractory lesions, case reports describe using dapsone, thalidomide, methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, 9 and TNF inhibitors such as infliximab and adalimumab. 2,9 In addition to medical treatment of MCD, it is important to consider the psychosocial morbidity, particularly for genital MCD.…”

Section: (Continues)mentioning

confidence: 99%

See 2 more Smart Citations

Cutaneous manifestations of metastatic Crohn's disease

Schneider

Foster²,

Patel

et al. 2018

Pediatric Dermatology

View full text Add to dashboard Cite

Metastatic Crohn's disease is a rare cutaneous complication of primary Crohn's disease. It is a granulomatous inflammatory process, similar to the pathogenic mechanism of Crohn's disease, that occurs in sites discontiguous from the gastrointestinal tract. Metastatic Crohn's disease can precede the development of Crohn's disease by months to years, and children are more likely to present with metastatic Crohn's disease in the absence of gastrointestinal symptoms. Given that approximately 30% of individuals with Crohn's disease present in childhood, early recognition of extraintestinal manifestations of Crohn's disease such as metastatic Crohn's disease can aid in timely diagnosis and management of bowel disease. We present data from two pediatric cases of metastatic Crohn's disease recently seen at our institution in addition to the 61 reported cases of pediatric metastatic Crohn's disease in the literature. This review article will focus on the epidemiology, pathogenesis, clinical features, and histology of and treatment options for pediatric metastatic Crohn's disease.

show abstract

Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management

Garber

Regueiro

2019

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Adalimumab for cutaneous metastatic Crohnʼs disease

Cited by 18 publications

References 7 publications

Metastatic Crohn’s Disease: An Approach to an Uncommon but Important Cutaneous Disorder

Metastatic Crohn’s Disease: An Approach to an Uncommon but Important Cutaneous Disorder

Cutaneous manifestations of metastatic Crohn's disease

Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management

Contact Info

Product

Resources

About